Rheumatology Medical News about rheumatoid arthritis;Certolizumab pegol

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Certolizumab pegol for rheumatoid arthritis: Effective in combination with methotrexate or as monotherapy
International Journal of Clinical Rheumatology, 06/22/09

Mease PJ – TNF plays an important role in several disease states, including rheumatoid arthritis. However, patient responses to these agents in clinical practice may be variable and additional agents are needed. Certolizumab pegol is the only PEGylated anti-TNF that is now approved for the treatment of patients with rheumatoid arthritis. This article summarizes the published efficacy, safety and patient-reported health outcome results for certolizumab pegol in the treatment of patients with active rheumatoid arthritis who have experienced an inadequate response to treatment with DMARDs, including methotrexate.

<< Previous
Biologic therapy in primary systemic vasculitis of the young

Next >>
Rituximab treatment of the anti-synthetase syndrome—a...

Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09 Relevance Score: 71%

Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09 Relevance Score: 70%

Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09 Relevance Score: 70%

Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09 Relevance Score: 69%

Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09 Relevance Score: 69%